↓ Skip to main content

Diabetes - Perspectives in Drug Therapy

Overview of attention for book
Cover of 'Diabetes - Perspectives in Drug Therapy'

Table of Contents

  1. Altmetric Badge
    Book Overview
  2. Altmetric Badge
    Chapter 1 Targeting type 2 diabetes.
  3. Altmetric Badge
    Chapter 2 Dual acting and pan-PPAR activators as potential anti-diabetic therapies.
  4. Altmetric Badge
    Chapter 3 GLP-1 agonists and dipeptidyl-peptidase IV inhibitors.
  5. Altmetric Badge
    Chapter 4 Cannabinoids and endocannabinoids in metabolic disorders with focus on diabetes.
  6. Altmetric Badge
    Chapter 5 SGLT inhibitors as new therapeutic tools in the treatment of diabetes.
  7. Altmetric Badge
    Chapter 6 Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 in antidiabetic therapy.
  8. Altmetric Badge
    Chapter 7 Nampt and its potential role in inflammation and type 2 diabetes.
  9. Altmetric Badge
    Chapter 8 Inhibition of ganglioside biosynthesis as a novel therapeutic approach in insulin resistance.
  10. Altmetric Badge
    Chapter 9 Overcoming Insulin Resistance with Ciliary Neurotrophic Factor
  11. Altmetric Badge
    Chapter 10 Thermogenesis and related metabolic targets in anti-diabetic therapy.
  12. Altmetric Badge
    Chapter 11 Interleukin-targeted therapy for metabolic syndrome and type 2 diabetes.
  13. Altmetric Badge
    Chapter 12 Fructose-1, 6-bisphosphatase inhibitors for reducing excessive endogenous glucose production in type 2 diabetes.
  14. Altmetric Badge
    Chapter 13 AMP-activated protein kinase and metabolic control.
  15. Altmetric Badge
    Chapter 14 Mitochondria as potential targets in antidiabetic therapy.
  16. Altmetric Badge
    Chapter 15 Research and development of glucokinase activators for diabetes therapy: theoretical and practical aspects.
  17. Altmetric Badge
    Chapter 16 Erratum to Chapter 11: Interleukin-Targeted Therapy for Metabolic Syndrome and Type 2 Diabetes
Attention for Chapter 4: Cannabinoids and endocannabinoids in metabolic disorders with focus on diabetes.
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#43 of 528)
  • High Attention Score compared to outputs of the same age (91st percentile)

Mentioned by

19 tweeters
2 Facebook pages
2 video uploaders


12 Dimensions

Readers on

106 Mendeley
1 CiteULike
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Chapter title
Cannabinoids and endocannabinoids in metabolic disorders with focus on diabetes.
Chapter number 4
Book title
Diabetes - Perspectives in Drug Therapy
Published in
Handbook of experimental pharmacology, April 2011
DOI 10.1007/978-3-642-17214-4_4
Pubmed ID
Book ISBNs
978-3-64-217213-7, 978-3-64-217214-4

Di Marzo V, Piscitelli F, Mechoulam R, Vincenzo Di Marzo, Fabiana Piscitelli, Raphael Mechoulam, Marzo, Vincenzo, Piscitelli, Fabiana, Mechoulam, Raphael


Prof.Dr.Dr. Mathias Schwanstecher


The cannabinoid receptors for Δ(9)-THC, and particularly, the CB(1) receptor, as well as its endogenous ligands, the endocannabinoids anandamide and 2-arachidonoylglycerol, are deeply involved in all aspects of the control of energy balance in mammals. While initially it was believed that this endocannabinoid signaling system would only facilitate energy intake, we now know that perhaps even more important functions of endocannabinoids and CB(1) receptors in this context are to enhance energy storage into the adipose tissue and reduce energy expenditure by influencing both lipid and glucose metabolism. Although normally well controlled by hormones and neuropeptides, both central and peripheral aspects of endocannabinoid regulation of energy balance can become dysregulated and contribute to obesity, dyslipidemia, and type 2 diabetes, thus raising the possibility that CB(1) antagonists might be used for the treatment of these metabolic disorders. On the other hand, evidence is emerging that some nonpsychotropic plant cannabinoids, such as cannabidiol, can be employed to retard β-cell damage in type 1 diabetes. These novel aspects of endocannabinoid research are reviewed in this chapter, with emphasis on the biological effects of plant cannabinoids and endocannabinoid receptor antagonists in diabetes.

Twitter Demographics

The data shown below were collected from the profiles of 19 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 106 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 2 2%
United Kingdom 1 <1%
Unknown 103 97%

Demographic breakdown

Readers by professional status Count As %
Researcher 21 20%
Student > Bachelor 16 15%
Student > Master 14 13%
Student > Ph. D. Student 11 10%
Other 10 9%
Other 16 15%
Unknown 18 17%
Readers by discipline Count As %
Medicine and Dentistry 21 20%
Agricultural and Biological Sciences 13 12%
Biochemistry, Genetics and Molecular Biology 10 9%
Neuroscience 8 8%
Pharmacology, Toxicology and Pharmaceutical Science 8 8%
Other 20 19%
Unknown 26 25%

Attention Score in Context

This research output has an Altmetric Attention Score of 18. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 January 2021.
All research outputs
of 17,520,458 outputs
Outputs from Handbook of experimental pharmacology
of 528 outputs
Outputs of similar age
of 164,334 outputs
Outputs of similar age from Handbook of experimental pharmacology
of 1 outputs
Altmetric has tracked 17,520,458 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 528 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.9. This one has done particularly well, scoring higher than 91% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 164,334 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 91% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them